ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

The advent of immunological therapies has revolutionized the treatment of solid and
haematological cancers over the last decade. Licensed therapies which activate the immune …

T-cell therapies, such as chimeric antigen receptor (CAR) T-cell, bispecific T-cell engager
(BiTE) and tumor-infiltrating lymphocyte (TIL) therapies, fight cancer cells harboring specific …

Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …

Immunotherapy revolutionised oncology by harnessing the native immune system to
effectively treat a wide variety of malignancies even at advanced stages. Off-target immune …

Introduction As chimeric antigen receptor T-cell therapies are becoming increasingly
available in the armamentarium of the hematologist, there is an emerging need to monitor …

Background Chimeric antigen receptor T-cell (CAR-T) infusion is associated with early
toxicity. Yet, whether early toxicity development holds ramifications for long-term outcomes is …

As clinical advances with chimeric antigen receptor (CAR) T cells are increasingly described
and the potential for extending their therapeutic benefit grows, optimizing the …

Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting
chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and …

In addition to conventional chemoradiation and targeted cancer therapy, the use of immune
based therapies, specifically immune checkpoint inhibitors (ICIs) and chimeric antigen …